Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics (BNGO) announced a groundbreaking study published in Leukemia, demonstrating the effectiveness of optical genome mapping (OGM) in prognosticating myelodysplastic syndrome (MDS). The study, conducted on 101 newly diagnosed patients, revealed that OGM altered prognostic risk scores for 17-21% of subjects and uncovered additional pathogenic variants in 13%. Compared to traditional methods, OGM detected nearly twice the number of pathogenic structural variants. The combination of OGM with next-generation sequencing (NGS) elevated the detection of significant clonal abnormalities in 97 out of 101 cases, suggesting OGM's potential as a crucial cytogenetic tool.
Bionano Genomics (BNGO) announced a conference call and webcast on August 4, 2022, at 4:30 p.m. ET to discuss its Q2 2022 financial results and corporate progress. Participants can register for the call to receive a dial-in number and pin. The event will be accessible via their website, and a replay will be available for 30 days. Bionano focuses on genome analysis solutions, including optical genome mapping and diagnostic services aimed at advancing research and clinical outcomes in genetics.
Bionano Genomics (BNGO) announced its participation in the Cancer Genomics Consortium (CGC) 2022 Annual Meeting, featuring 18 events including panel discussions and scientific presentations. Dr. Alka Chaubey will lead a session on Optical Genome Mapping (OGM) integration with Next Generation Sequencing (NGS) for cancer research. The conference will take place from July 31 to August 3, 2022, in St. Louis, Missouri, showcasing advancements in clinical genomics. Bionano's involvement underscores the growing importance of OGM in cancer research, with numerous presentations highlighting its applications.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced a study highlighting the use of optical genome mapping (OGM) in analyzing changes in two induced pluripotent stem cell (iPSC) lines, WTC-11 and Tuba1-GFP, over 150 days. The research revealed significant genomic alterations, including hundreds of structural variants (SVs) undetected by traditional cytogenetic methods. This supports OGM's potential in regenerative medicine while raising concerns about the limitations of long-term iPSC culture. The findings accentuate OGM's value in pharmaceutical research and drug development.
Bionano Genomics (BNGO) announced the issuance of US Patent No. 11,359,244 on June 14, 2022, which covers methods for analyzing small nucleic acid fragments in nanochannel arrays. This patent relates to Bionano’s Saphyr® system, aiding in the detection of various genetic abnormalities. The technology could lead to future applications in non-invasive prenatal testing and oncology. The patent strengthens Bionano's intellectual property portfolio in genome analysis.
Bionano Genomics (BNGO) announced its participation in the EACR 2022 Congress in Seville, Spain, from June 20-23, 2022. The event will showcase Bionano's Saphyr system, NxClinical software, and expert services focused on cancer research. Key presentations will highlight the application of Optical Genome Mapping (OGM) in solid tumor analysis, including insights into pediatric CNS tumors and Ewing sarcoma. The latest NxClinical software update enhances genomic analysis capabilities for clinical researchers. This event aligns with Bionano's mission to enhance clinical research tools for cancer diagnostics.
Bionano Genomics (BNGO) showcased its Long String VANTAGE automation solution for Ultra High Molecular Weight DNA extraction at the ESHG 2022 Conference, aimed at enhancing optical genome mapping (OGM) capabilities. The collaboration with Hamilton signifies a major leap in laboratory automation efficiency. The conference featured 13 presentations highlighting OGM's role in identifying rare undiagnosed genetic diseases. CEO Erik Holmlin emphasized the potential benefits of OGM as a cost-effective and rapid alternative to traditional methods.
Bionano Genomics partnered with Hamilton to develop the Long String VANTAGE, an automated system for isolating Ultra High Molecular Weight (UHMW) DNA, enhancing throughput and quality. This innovation allows the extraction of up to 12 UHMW DNA samples in under 4 hours, double the manual output, ensuring high consistency. The collaboration aims to improve optical genome mapping applications and plans to test the system with select clinical laboratories for commercial release by the end of 2022. This automation is expected to enhance workflow efficiency in genomic analysis.
Bionano Genomics (Nasdaq: BNGO) announced a study published in Cell showcasing the effectiveness of optical genome mapping (OGM) in detecting inversions linked to genetic disorders. The research found that 80% of larger detected inversions were balanced and associated with various health issues, including pediatric autism. Analyzing 41 human samples, the study identified 40 recurrent inversions affecting 0.6% of the genome. Erik Holmlin, CEO, emphasized that OGM could make inversion analysis routine in genetic diagnostics.
Bionano Genomics (BNGO) has announced a two-hour presentation on Optical Genome Mapping (OGM) technologies by researchers from leading institutions at the Canadian College of Medical Geneticists (CCMG) General Meeting 2022, scheduled from June 6-10. The workshop, titled New Technologies and Applications of Optical Genome Mapping, will take place on June 8, featuring esteemed presenters from Columbia University Medical Center and University Health Network. This highlights Bionano's commitment to advancing genomic research and applications related to prenatal testing and cancer diagnostics.